The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro

COH29 [N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase (RNR). This key enzyme in deoxyribonucleotide biosy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Pharmacol
Autori principali: Chen, Mei-Chuan, Zhou, Bingsen, Zhang, Keqiang, Yuan, Yate-Ching, Un, Frank, Hu, Shuya, Chou, Chih-Ming, Chen, Chun-Han, Wu, Jun, Wang, Yan, Liu, Xiyong, Smith, D. Lynne, Li, Hongzhi, Liu, Zheng, Warden, Charles D., Su, Leila, Malkas, Linda H., Chung, Young Min, Hu, Mickey C.-T., Yen, Yun
Natura: Artigo
Lingua:Inglês
Pubblicazione: The American Society for Pharmacology and Experimental Therapeutics 2015
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4429719/
https://ncbi.nlm.nih.gov/pubmed/25814515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.114.094987
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi